Olaparib prolongs overall survival compared with enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and gene alterations in BRCA1, BRCA2, or ATM, according to the final survival analysis of the phase 3 PROfound trial. These results were presented yesterday at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and simultaneously published in the New England Journal of Medicine. "Metastatic castration-resistant prostate cancer r...

Because prostate cancer cases are often localized and controlled, men can survive many years after diagnosis. However, that is not the case for metastatic castration-resistant prostate cancer (mCRPC): after diagnosis, less than a third of men survive five years. In the treatment of prostate cancer, hormone therapy is commonly used to suppress androgen receptors in order to prevent testosterone from being produced, thereby killing the malignant tumor. Unfortunately, this does not work for mCRPC. ...

In the case of metastatic castration-resistant prostate cancer (mCRPC), mutations in germline DNA damage repair (gDDR) genes are found in a significant percentage of patients. However, the consequences of these mutations have until now been unknown. Scientists from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have contributed to understanding the connection between mCRPC and germline mutations. In the researchers' study, published in the Journa...

​Results are in for the ERA 223 study, a phase 3 trial which examined adding radium-223 to abiraterone acetate and prednisone or prednisolone for patients with castration-resistant prostate cancer (CRPC) and bone metastasis. Previous studies have found that radium-223 prolongs overall survival and delays the onset of symptomatic skeletal events in patients with CRPC and bone metastasis, and the combination of abiraterone acetate plus prednisone or prednisolone has been shown to improve...